• Open Access

Detection of Clinically Relevant Pain Relief in Cats with Degenerative Joint Disease Associated Pain

Authors

  • M.E. Gruen,

    1. Comparative Pain Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, Raleigh, NC
    Search for more papers by this author
  • E. Griffith,

    1. Department of Statistics, North Carolina State University, Raleigh, NC
    Search for more papers by this author
  • A. Thomson,

    1. Comparative Pain Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, Raleigh, NC
    Search for more papers by this author
  • W. Simpson,

    1. Morrisville Cat Hospital, Morrisville, NC
    Search for more papers by this author
  • B.D.X. Lascelles

    Corresponding author
    1. Comparative Pain Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, Raleigh, NC
    2. Center for Comparative Medicine and Translational Research, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
    • Corresponding author: B.D.X. Lascelles, Comparative Pain Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607; e-mail: duncan_lascelles@ncsu.edu.

    Search for more papers by this author

Abstract

Background

Detection of clinically relevant pain relief in cats with degenerative joint disease (DJD) is complicated by a lack of validated outcome measures and a placebo effect.

Hypothesis/Objectives

To evaluate a novel approach for detection of pain relief in cats with DJD.

Animals

Fifty-eight client-owned cats.

Methods

Prospective, double-masked, placebo-controlled, stratified, randomized, clinical study. Enrolled cats were 6–21 years of age, with owner-observed mobility impairment, evidence of pain in at least 2 joints during orthopedic examination, and overlapping radiographic evidence of DJD, and underwent a 2-week baseline period, 3-week treatment period with placebo or meloxicam, and 3-week masked washout period. Outcome measures were evaluated at days 0, 15, 36, and 57.

Results

Both groups significantly improved after the treatment period (day 36) on client-specific outcome measures (CSOM) and feline musculoskeletal pain index (FMPI) (P < .0001 for both); there was no difference between the groups on CSOM or FMPI score improvement. After the masked washout period, more cats that received meloxicam during the treatment period had a clinically relevant decrease in CSOM score (P = .048) and FMPI score (P = .021) than cats that received placebo.

Conclusions and Clinical Importance

Using both a client-specific and a general clinical metrology instrument, owners of cats with DJD were able to detect evident recurrence of clinical signs after withdrawal of active medication than after withdrawal of placebo, and that this study design might be a novel and useful way to circumvent the placebo effect and detect the efficacy of pain-relieving medications.

Ancillary